Development of a broad-spectrum antiviral with activity against Ebola virus

M. Javad Aman, Michael S. Kinch*, Kelly Warfield, Travis Warren, Abdul Yunus, Sven Enterlein, Eric Stavale, Peifang Wang, Shaojing Chang, Qingsong Tang, Kevin Porter, Michael Goldblatt, Sina Bavari

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

84 Scopus citations

Abstract

We report herein the identification of a small molecule therapeutic, FGI-106, which displays potent and broad-spectrum inhibition of lethal viral hemorrhagic fevers pathogens, including Ebola, Rift Valley and Dengue Fever viruses, in cell-based assays. Using mouse models of Ebola virus, we further demonstrate that FGI-106 can protect animals from an otherwise lethal infection when used either in a prophylactic or therapeutic setting. A single treatment, administered 1 day after infection, is sufficient to protect animals from lethal Ebola virus challenge. Cell-based assays also identified inhibitory activity against divergent virus families, which supports a hypothesis that FGI-106 interferes with a common pathway utilized by different viruses. These findings suggest FGI-106 may provide an opportunity for targeting viral diseases.

Original languageEnglish
Pages (from-to)245-251
Number of pages7
JournalAntiviral Research
Volume83
Issue number3
DOIs
StatePublished - Sep 2009
Externally publishedYes

Keywords

  • Antiviral
  • Dengue Fever
  • Ebola virus

Fingerprint

Dive into the research topics of 'Development of a broad-spectrum antiviral with activity against Ebola virus'. Together they form a unique fingerprint.

Cite this